Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in South Carolina: - Ralph H Johnson VA Medical Center — Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- Saint Francis Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in South Carolina: - St Francis Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Bon Secours Saint Francis Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in South Carolina: - Medical University of South Carolina /ID# 259692 — Charleston, South Carolina
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in South Carolina: - Research Site — Charleston, South Carolina
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in South Carolina: - Medical University of South Carolina (MUSC) — Charleston, South Carolina
- Gibbs Cancer Center — Spartanburg, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in South Carolina: - Local Institution - 0227 — Charleston, South Carolina
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in South Carolina: - GC2202 Study Site 110 — Rockville, South Carolina
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in South Carolina: - SC Cancer Specialists at St. Joseph's/Candler Bluffton — Bluffton, South Carolina
- St. Joseph's/Candler Smith — Bluffton, South Carolina
- Summit Cancer Care at St. Josph's/Candler Bluffton — Bluffton, South Carolina
- South Carolina Cancer Specialists — Hilton Head Island, South Carolina
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in South Carolina: - Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in South Carolina: - Roper Saint Francis Healthcare- Site Number : 8400013 — Charleston, South Carolina
- Prisma Health Cancer Institute - Greenville- Site Number : 8400019 — Greenville, South Carolina
- Gibbs Cancer Center & Research Institute - Spartanburg- Site Number : 8400001 — Spartanburg, South Carolina
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- McLeod Health — Florence, South Carolina
Recruiting NIH
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina